SymBio Pharmaceuticals Limited (SYMQY)

Market Cap	47.56M -13.0%
Revenue (ttm)	8.34M -46.7%
Net Income	-30.46M
EPS	-0.61
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,461
Open	0.5579
Previous Close	0.5579
Day's Range	0.5579 - 0.5579
52-Week Range	0.5579 - 1.3100
Beta	0.46
RSI	16.41
Earnings Date	May 7, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses. The company was incorporated in 2005 and is bas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 91
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYMQY

Financial Performance

In 2025, SymBio Pharmaceuticals's revenue was 1.31 billion, a decrease of -46.67% compared to the previous year's 2.45 billion. Losses were -4.78 billion, 24.6% more than in 2024.

Financial numbers in JPY